Managed Care - January 2009 - (Page CB-A6)
Psoriasis has a documented occupational impact, including a negative effect on work productivity, job retention, and the amount of days missed on the job (Schmitt 2006). In addition, more than half of NPF respondents have reported that psoriasis impairs their ability to work, either partially (35 percent) or completely (17 percent) (NPF 2004). An analysis of NPF surveys conducted between 2003 and 2005 found that when compared to patients with mild psoriasis, people with severe psoriasis were more likely to have annual household income of less than $30,000 (Horn 2007b). In addition, another study found that for those patients with severe psoriasis, more than half were not working or retired, and of these patients, 34 percent attributed their inability to retain a job to their disease (Finlay 1995). Employed patients reported having missed a mean of 26 days from work per year as a result of their condition (Finlay 1995). Summary Numerous unmet needs exist among people with psoriasis. In the absence of a cure, psoriasis patients seek treatment that improves signs and symptoms of their disease. Much progress has been made in the area of treatment options, but substantial gaps still exist. References Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995;132:236–244. Fortune DG, Richards HL, Main CJ, et al. What patients with psoriasis believe about their condition. J Am Acad Dermatol. 1998;39:196–201. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006a;296:1735–1741. Gelfand JM, Shin DB, Neimann AL, et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006b;126:2194–2201. Gelfand JM, Troxel AB, Lewis JB, et al. The risk of mortality in patients with psoriasis. Arch Dermatol. 2007;143:1493–1499. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med. 1995;332:581–588. Gupta MA, Gupta AK. Perceived deprivation of social touch in psoriasis is associated with greater psychologic morbidity: an index of the stigma experience in dermatologic disorders. Cutis. 1998;61:339–342. Gupta MA, Schork NJ, Gupta AK, et al. Suicidal ideation in psoriasis. Int J Dermatol. 1993;32:189–190. Herron MD, Hinckley BA, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Der- matol. 2005;141:1527–1534. Horn EJ, Fox KM, Patel V, et al. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol. 2007a;57:957–962. Horn EJ, Fox KM, Patel V, et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol. 2007b;57:963–971. Kourosh AS, Miner A, Menter A. Psoriasis as the marker of underlying systemic disease. Skin Therapy Lett. 2008;13:1–5. Krueger G, Feldman SR, Camisa C, et al. Two consideration for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treatment psoriasis? J Am Acad Dermatol. 2000;43:281–285. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life. Arch Dermatol. 2001;137:280–284. Lebwohl M, Bagel J, Gelfand JM, et al. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol. 2008;58:94–105. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004;19:225–230. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–850. Nijsten T, Rolstad T, Feldman SR, Stern RS. Members of the National Psoriasis Foundation: more extensive disease and better informed about treatment options. Arch Dermatol. 2005;141: 19–26. NPF (National Psoriasis Foundation). About psoriasis. 2008. «http://www.psoriasis.org/about/psoriasis/». Accessed Nov. 21, 2008. NPF (National Psoriasis Foundation). Survey panels, Spring 2004 through Fall 2004. «http://www.psoriasis.org/research/ foundation/survey_panels.php». Accessed Oct. 7, 2008. NPF (National Psoriasis Foundation). Survey panels, Spring 2005 through Fall 2005. «http://www.psoriasis.org/research/ foundation/survey_panels.php». Accessed Oct. 7, 2008. NPF (National Psoriasis Foundation). Survey panels, Spring 2006 through Fall 2006. «http://www.psoriasis.org/research/ foundation/survey_panels.php». Accessed Oct. 7, 2008. NPF (National Psoriasis Foundation). Survey panels, Spring 2007 through Fall 2007. «http://www.psoriasis.org/research/ foundation/survey_panels.php». Accessed Oct. 7, 2008. Patel V, Horn EJ, Lobosco SJ, et al. Psoriasis treatment patterns: results of a cross-sectional survey of dermatologists. J Am Acad Dermatol. 2008;58:964–969. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major diseases. J Am Dermatol. 1999;41:401–407. Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology. 2006;213: 102–110. 6
If you would like to try to load the digital publication without using Flash Player detection, please click here.